{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T20:49:57Z","timestamp":1781902197336,"version":"3.54.5"},"reference-count":94,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.ijpharm.2015.05.024","type":"journal-article","created":{"date-parts":[[2015,5,15]],"date-time":"2015-05-15T22:41:11Z","timestamp":1431729671000},"page":"55-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Effects of formulation design on niacin therapeutics: mechanism of action, metabolism, and drug delivery"],"prefix":"10.1016","volume":"490","author":[{"given":"Dustin L.","family":"Cooper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek E.","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Roane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2631-3756","authenticated-orcid":false,"given":"Sam","family":"Harirforoosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2015.05.024_bib0005","unstructured":"AHFS Drug Information\u00ae, 56th ed. American Society of Health-System Pharmacists, Bethesda, MD, 2015."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3810\/pgm.2011.03.2265","article-title":"Important considerations for treatment with dietary supplement versus prescription niacin products","volume":"123","author":"Backes","year":"2011","journal-title":"Postgraduate Med."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0015","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1567-5688(11)70885-6","article-title":"HDL-C: role as a risk modifier","volume":"Supplements 12","author":"Barter","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.hrtlng.2010.07.019","article-title":"A case for immediate-release niacin","volume":"41","author":"Bassan","year":"2012","journal-title":"Heart Lung: J. Crit. Care"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0025","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1586\/14779072.2.4.485","article-title":"Extended-release niacin\/lovastatin: the first combination product for dyslipidemia","volume":"2","author":"Bays","year":"2004","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0030","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0002-9149(03)00007-9","article-title":"Comparison of once-daily, niacin extended-release\/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor versus other cholesterol-modulating agents trial evaluation [ADVOCATE])","volume":"91","author":"Bays","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0035","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1161\/01.ATV.0000144010.55563.63","article-title":"Lipoprotein(a): an elusive cardiovascular risk factor","volume":"24","author":"Berglund","year":"2004","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0040","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1525-139X.2008.00426.x","article-title":"Niacin and related compounds for treating hyperphosphatemia in dialysis patients","volume":"21","author":"Berns","year":"2008","journal-title":"Semin. Dialysis"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0045","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cld.2007.06.010","article-title":"Lipid-lowering agents that cause drug-induced hepatotoxicity","volume":"11","author":"Bhardwaj","year":"2007","journal-title":"Clin. Liver Dis."},{"issue":"Suppl 2","key":"10.1016\/j.ijpharm.2015.05.024_bib0050","doi-asserted-by":"crossref","first-page":"S373","DOI":"10.2337\/dc09-S343","article-title":"Triglycerides and HDL cholesterol: stars or second leads in diabetes?","volume":"32","author":"Bitzur","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0055","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/jps.2600701210","article-title":"Interaction of tablet disintegrants and magnesium stearate during mixing I: effect on tablet disintegration","volume":"70","author":"Bolhuis","year":"1981","journal-title":"J. Pharma. Sci."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0060","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1600-0625.2000.009003165.x","article-title":"The 500 Dalton rule for the skin penetration of chemical compounds and drugs","volume":"9","author":"Bos","year":"2000","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0065","first-page":"234","article-title":"Can niacin slow the development of atherosclerosis in coronary artery disease patients already taking statins? Nature clinical practice","volume":"2","author":"Brown","year":"2005","journal-title":"Cardiovas. Med."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0070","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0075","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1368-5031.2004.00233.x","article-title":"Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug","volume":"58","author":"Carlson","year":"2004","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2796.1989.tb01393.x","article-title":"Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid","volume":"226","author":"Carlson","year":"1989","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0085","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ijcard.2011.12.103","article-title":"Lipid-altering efficacy and safety profile of co-administered extended release niacin\/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia","volume":"167","author":"Chen","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0090","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1194\/jlr.M029769","article-title":"Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice","volume":"53","author":"Chennamsetty","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0095","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/hq0801.095151","article-title":"Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL","volume":"21","author":"Cheung","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0100","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2147\/BTT.S3959","article-title":"Effect of extended-release niacin on hormone-sensitive lipase and lipoprotein lipase in patients with HIV-associated lipodystrophy syndrome","volume":"2","author":"Chow","year":"2008","journal-title":"Biologics Targets Ther."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0105","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1208\/s12249-010-9543-4","article-title":"Formulation of controlled-release capsules of biopharmaceutical classification system I drugs using niacin as a model","volume":"11","author":"Chuong","year":"2010","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0110","first-page":"1211","article-title":"Identifying and managing patients with hyperlipidemia","volume":"3","author":"Clark","year":"1997","journal-title":"Am. J. Manage. Care"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0115","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/IJN.S596","article-title":"Drug delivery and nanoparticles:applications and hazards","volume":"3","author":"De Jong","year":"2008","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.clnu.2014.09.019","article-title":"Effect of niacin on lipids and glucose in patients with type 2 diabetes: A meta-analysis of randomized, controlled clinical trials","author":"Ding","year":"2014","journal-title":"Clinical nutrition."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0125","first-page":"692530","article-title":"Acute liver failure secondary to niacin toxicity","volume":"2014","author":"Ellsworth","year":"2014","journal-title":"Case Rep. Pediatr."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0130","unstructured":"Endurance Products Company, 2014. Endur-acin 500mg. Endurance Products Company, Tigard, OR."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0135","first-page":"410","article-title":"Fulminant hepatic failure following low-dose sustained-release niacin therapy in hospital","volume":"155","author":"Fischer","year":"1991","journal-title":"West. J. Med."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0140","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0955-2863(02)00284-X","article-title":"Niacin and cholesterol: role in cardiovascular disease (review)","volume":"14","author":"Ganji","year":"2003","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0145","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1194\/jlr.M300403-JLR200","article-title":"Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells","volume":"45","author":"Ganji","year":"2004","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0150","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00132580-200203000-00010","article-title":"Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia","volume":"4","author":"Gupta","year":"2002","journal-title":"Heart Dis."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0155","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1517\/14656566.5.6.1385","article-title":"Extended-release niacin for modifying the lipoprotein profile","volume":"5","author":"Guyton","year":"2004","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0160","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1001\/archinte.160.8.1177","article-title":"Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil StudyGroup","volume":"160","author":"Guyton","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0165","doi-asserted-by":"crossref","unstructured":"Guyton, J.R., Capuzzi, D.M., 1998. Treatment of hyperlipidemia with combined niacin-statin regimens. The American journal of cardiology 82, 82U-84U; discussion 85\u201386U.","DOI":"10.1016\/S0002-9149(98)00955-2"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0170","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurheartj\/eht055","article-title":"HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin\/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment","volume":"34","author":"HPS THRIVE Collaborative Group","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0175","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"HPS2-THRIVE Collaborative Group","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0180","first-page":"S315","article-title":"Niacin-based therapy for dyslipidemia: past evidence and future advances","volume":"8","author":"Ito","year":"2002","journal-title":"Am. J. Manage. Care"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0185","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1600-0625.2007.00553.x","article-title":"A topical lipophilic niacin derivative increases NAD, epidermal differentiation and barrier function in photodamaged skin","volume":"16","author":"Jacobson","year":"2007","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0190","doi-asserted-by":"crossref","first-page":"365","DOI":"10.4065\/mcp.2009.0535","article-title":"A hot topic in dyslipidemia management\u2013how to beat a flush: optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention","volume":"85","author":"Jacobson","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0195","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.clinthera.2009.01.011","article-title":"Patients\u2019 experiences of niacin-induced flushing in clinical practice: a structured telephone interview","volume":"31","author":"Kamal-Bahl","year":"2009","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0200","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1111\/j.1742-1241.2009.02099.x","article-title":"The mechanism and mitigation of niacin-induced flushing","volume":"63","author":"Kamanna","year":"2009","journal-title":"Int. J. Clin. Prac."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0205","doi-asserted-by":"crossref","first-page":"20B","DOI":"10.1016\/j.amjcard.2008.02.029","article-title":"Mechanism of action of niacin","volume":"101","author":"Kamanna","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0210","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/archinte.1991.00400070172024","article-title":"Niacin revisited. A randomized: controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia","volume":"151","author":"Keenan","year":"1991","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5339\/gcsp.2014.3","article-title":"The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina","volume":"2014","author":"Khan","year":"2014","journal-title":"Global Cardiol. Sci. Prac."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0220","doi-asserted-by":"crossref","first-page":"24U","DOI":"10.1016\/S0002-9149(98)00847-9","article-title":"Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing","volume":"82","author":"Knopp","year":"1998","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0225","doi-asserted-by":"crossref","first-page":"51L","DOI":"10.1016\/S0002-9149(00)01471-5","article-title":"Evaluating niacin in its various forms","volume":"86","author":"Knopp","year":"2000","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.colsurfb.2009.09.001","article-title":"Biodegradable polymeric nanoparticles based drug delivery systems","volume":"75","author":"Kumari","year":"2010","journal-title":"Colloids Surf. B"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0235","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.bcp.2010.07.023","article-title":"Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes","volume":"80","author":"Li","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0240","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.atherosclerosis.2008.11.026","article-title":"Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance","volume":"205","author":"Linke","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0245","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/11202560-000000000-00000","article-title":"Niacin extended release (ER)\/simvastatin (Simcor(R)): a guide to its use in lipid regulation","volume":"10","author":"Lyseng-Williamson","year":"2010","journal-title":"Drugs R&D"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0250","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1742-1241.2008.01938.x","article-title":"Lipid-modifying efficacy and tolerability of extended-release niacin\/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia","volume":"62","author":"Maccubbin","year":"2008","journal-title":"Int. J. Clin. Prac."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0255","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.amjcard.2009.02.047","article-title":"Flushing profile of extended-release niacin\/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease","volume":"104","author":"Maccubbin","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0260","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.amjcard.2012.05.009","article-title":"Effectiveness and safety of laropiprant on niacin-induced flushing","volume":"110","author":"Maccubbin","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0265","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1753-4887.2012.00479.x","article-title":"Niacin: chemical forms, bioavailability, and health effects","volume":"70","author":"MacKay","year":"2012","journal-title":"Nutr. Rev."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0270","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4103\/0250-474X.59549","article-title":"Design and evaluation of niacin microspheres","volume":"71","author":"Maravajhala","year":"2009","journal-title":"Indian J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0275","first-page":"3071","article-title":"Critical evaluation of biodegradable polymers used in nanodrugs","volume":"8","author":"Marin","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0280","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.atherosclerosis.2013.06.006","article-title":"HPS2-THRIVE results: bad for niacin\/laropiprant, good for ezetimibe?","volume":"229","author":"Masana","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0285","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.2165\/00003495-200565180-00014","article-title":"Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia","volume":"65","author":"McCormack","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0290","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/ajhp\/60.10.995","article-title":"Niacin for dyslipidemia: considerations in product selection","volume":"60","author":"McKenney","year":"2003","journal-title":"Am. J. Health-Syst. Pharm. AJHP: Off. J. Am. Soc. Health-Syst. Pharm."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0295","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1001\/archinte.164.7.697","article-title":"New perspectives on the use of niacin in the treatment of lipid disorders","volume":"164","author":"McKenney","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0300","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/ajcn\/10.4.285","article-title":"On the mechanism of action of nicotinic acid in lowering serum lipids","volume":"10","author":"Miller","year":"1962","journal-title":"The American journal of clinical nutrition"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0305","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1517\/14656566.3.12.1763","article-title":"Niacin extended-release\/lovastatin: combination therapy for lipid disorders","volume":"3","author":"Moon","year":"2002","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0310","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jacl.2007.09.001","article-title":"Effects of adding extended-release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease","volume":"1","author":"Moore","year":"2007","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0315","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0021-9150(90)90093-X","article-title":"Reduction of serum lipoprotein(a) levels in hyperlipidaemic patients with alpha-tocopheryl nicotinate","volume":"84","author":"Noma","year":"1990","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0320","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.2147\/VHRM.S3460","article-title":"Targeting multiple dyslipidemias with fixed combinations\u2013focus on extended release niacin and simvastatin","volume":"4","author":"Pandian","year":"2008","journal-title":"Vasc. Health Risk Manage."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0325","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.amjcard.2007.10.023","article-title":"Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia","volume":"101","author":"Paolini","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0330","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4155\/tde.10.16","article-title":"Challenges and opportunities in dermal\/transdermal delivery","volume":"1","author":"Paudel","year":"2010","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0335","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2165\/11203730-000000000-00000","article-title":"Extended-release niacin (nicotinic acid)\/laropiprant","volume":"69","author":"Perry","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0340","first-page":"S308","article-title":"Understanding niacin formulations","volume":"8","author":"Pieper","year":"2002","journal-title":"Am. J. Manage. Care"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0345","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1093\/ajhp\/60.suppl_2.S9","article-title":"Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety","volume":"60","author":"Pieper","year":"2003","journal-title":"Am. J. Health-Syst. Phar. AJHP: Off. J. Am. Soc. Health-Syst. Pharm."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0350","doi-asserted-by":"crossref","first-page":"35L","DOI":"10.1016\/S0002-9149(00)01468-5","article-title":"The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol","volume":"86","author":"Piepho","year":"2000","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0355","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1172\/JCI27160","article-title":"Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid","volume":"115","author":"Pike","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0360","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/nbt.1504","article-title":"Transdermal drug delivery","volume":"26","author":"Prausnitz","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0365","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.1981.57","article-title":"Transdermal scopolamine in the prevention of motion sickness at sea","volume":"29","author":"Price","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0370","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/ijcp.12213","article-title":"The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy","volume":"67","author":"Rhodes","year":"2013","journal-title":"Int. J. Clin. Prac."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0375","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/HCO.0b013e3283410c16","article-title":"Effects of niacin on atherosclerosis and vascular function","volume":"26","author":"Ruparelia","year":"2011","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0380","unstructured":"RxList, 2014. Advicor drug. WebMD, New York."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0385","unstructured":"RxList, 2014. Niacor drug. WebMD, New York."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0390","unstructured":"RxList, 2014. Niaspan drug. WebMD, New York."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0395","unstructured":"RxList, 2014. Simcor drug. WebMD, New York."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0400","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1161\/hq1001.096624","article-title":"Niacin but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol","volume":"21","author":"Sakai","year":"2001","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0405","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1517\/14656566.8.11.1711","article-title":"Present-day uses of niacin: effects on lipid and non-lipid parameters","volume":"8","author":"Sanyal","year":"2007","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0410","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/jps.2600700609","article-title":"Carboxymethylcellulose: effect of degree of polymerization and substitution on tablet disintegration and dissolution","volume":"70","author":"Shah","year":"1981","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0415","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1742-1241.2010.02370.x","article-title":"Efficacy and safety of extended-release niacin\/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia","volume":"64","author":"Shah","year":"2010","journal-title":"Int. J. Clin. Prac."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0420","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.biomaterials.2010.10.025","article-title":"Multivalent niacin nanoconjugates for delivery to cytoplasmic lipid droplets","volume":"32","author":"Sharma","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0425","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0168-3659(00)00339-4","article-title":"Biodegradable polymeric nanoparticles as drug delivery devices","volume":"70","author":"Soppimath","year":"2001","journal-title":"J. Controlled Release Off. J. Controlled Release Soc."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0430","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3109\/10837450.2012.727003","article-title":"Preparation and characterization of microemulsion formulations of nicotinic acid and its prodrugs for transdermal delivery","volume":"18","author":"Tashtoush","year":"2013","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0435","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"The Coronary Drug Project Research Group , Clofibrate and niacin in coronary heart disease","volume":"231","author":"The Coronary Drug Project Research Group","year":"1975","journal-title":"Jama"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0440","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11883-011-0212-1","article-title":"Niacin: the evidence, clinical use, and future directions","volume":"14","author":"Villines","year":"2012","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0445","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4137\/CMC.S7601","article-title":"Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters","volume":"5","author":"Vosper","year":"2011","journal-title":"Clin. Med. Insights. Cardiol."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0450","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/S0142-9612(03)00109-1","article-title":"Peripheral nerve regeneration with sustained release of poly(phosphoester) microencapsulated nerve growth factor within nerve guide conduits","volume":"24","author":"Xu","year":"2003","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0455","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1016\/S0142-9612(02)00116-3","article-title":"Polyphosphoester microspheres for sustained release of biologically active nerve growth factor","volume":"23","author":"Xu","year":"2002","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0460","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1517\/14656566.2012.690395","article-title":"Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety","volume":"13","author":"Yadav","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0465","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1345\/aph.1C161","article-title":"Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia","volume":"37","author":"Yim","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ijpharm.2015.05.024_bib0470","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.amjcard.2014.01.426","article-title":"Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease","volume":"113","author":"Zambon","year":"2014","journal-title":"Am. J. Cardiol."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517315004433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517315004433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,25]],"date-time":"2019-08-25T01:30:40Z","timestamp":1566696640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517315004433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":94,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0378517315004433"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2015.05.024","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of formulation design on niacin therapeutics: mechanism of action, metabolism, and drug delivery","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2015.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}